Potential benefits of proton beam therapy in patients with cardiac sarcoma
N.A. Vorobyov1–3, N.I. Martynova1, D.V. Bondarchuk1, D.A. Antipin1, A.V. Kubasov1, A.V. Mikhaylov1–3, A.I. Lyubinskiy1, G.I. Andreev1
1Berezin Sergey Medical Institute, St. Petersburg, Russian Federation
2St. Petersburg State University, St. Petersburg, Russian Federation
3I.I. Mechnikov North-Western State Medical University, St. Petersburg, Russian Federation
Cardiac sarcoma is a rare tumor with poor prognosis. These tumors have a very limited array of treatment options available due to their localization. The efficacy of chemotherapy and radiation therapy is poor as well. Nonetheless, radiation therapy may be considered first-line treatment in local recurrences after prior surgery and pharmacotherapy.
This paper describes case histories of two patients with cardiac sarcoma who received proton therapy and compares two radiation treatment schedules using proton beam or photon beam therapy. Follow-up was 8 months. No toxicity throughout the treatment and follow-up was reported. CT and MRI performed 3 and 6 months after radiation therapy have demonstrated tumor mass reduction in both patients. Photon beam radiation treatment schedules were generated to compare dose distributions. V5, V10, and mean left lung dose, heart V40, mean right lung dose, and radiation exposure to spinal cord were significantly lower in proton beam therapy.
In cardiac tumors, proton beam therapy helps significantly reduce radiation exposure to healthy tissues as compared with photon beam therapy. The result is better treatment tolerance as well as lower rate and severity of adverse effects of radiation therapy.
Keywords: proton beam therapy, cardiac sarcoma, Ewing’s sarcoma, radiation therapy, radiation dose.
For citation: Vorobyov N.A., Martynova N.I., Bondarchuk D.V. et al. Potential benefits of proton beam therapy in patients with cardiac sarcoma. Russian Medical Review. [Epub ahead of print]. DOI: 10.32364/2587-6821-2020-4-3.
DOI: 10.32364/2587-6821-2020-4-3
About the authors:
1–3Nikolay A. Vorobyov — MD, PhD, Head of the Department of Proton Beam Therapy, ORCID iD 0000-0002-6998-5771;
1Nataliya I. Martynova — MD, radiologist of the Department of Proton Beam Therapy, ORCID iD 0000-0002-1679-5173;
1Dmitriy V. Bondarchuk — MD, radiologist of the Department of Radiodiagnostics, ORCID iD 0000-0001-8752-0591;
1Denis A. Antipin — MD, radiologist of the Department of Proton Beam Therapy, ORCID iD 0000-0002-4198-3870;
1Anton V. Kubasov — medical physicist, ORCID iD 0000-0001-7672-6703;
1–3Alexey V. Mikhailov — MD, PhD, Head of the Department of Radiation Therapy, ORCID iD 0000-0002-5240-7203;
1Andrey I. Lyubinskiy — medical physicist, ORCID iD 0000-0002-5694-8701;
1Georgiy I. Andreev — Head of the Division of Medical Physics, ORCID iD 0000-0001-7590-5187.
1Berezin Sergey Medical Institute. 2 build. 3, Esenin str., St. Petersburg, 194354, Russian Federation.
2St. Petersburg State University. 7/9, Universitetskaya emb., St. Petersburg, 199034, Russian Federation.
3I.I. Mechnikov North-Western State Medical University. 41, Kirochnaya str., St. Petersburg, 191015, Russian Federation.
Contact information: Nikolay A. Vorob’ev, e-mail: vorobyov@ldc.ru. Financial Disclosure: no authors have a financial or property interest in any material or method mentioned. There is no conflict of interests. Received 20.02.2020.
2. Hata A., Katakami N., Fujita S. et al. Angiosarcoma arising from right atrium: Remarkable response to concurrent chemoradiotherapy with carboplatin and paclitaxel. J Thorac Oncol. 2011;6:970–971. DOI: 10.1097/JTO.0b013e318215a22b.
3. Franceschini D., Scotti V., Simontacchi G. et al. Application of helical tomotherapy for the treatment of a right atrium angiosarcoma: A case report. Tumori. 2013;99: e233–e236. DOI: 10.1177/030089161309900520.
4. Fehr M., Kuhn M., Mayer K. et al. Metastatic angiosarcoma arising from the right atrium: Unusual presentation and excellent response to treatment in a young patient. J Thorac Oncol. 2010;5:1301–1302. DOI: 10.1097/JTO.0b013e3181dd1c78.
5. Aoka Y., Kamada T., Kawana M. et al. Primary cardiac angiosarcoma treated with carbon-ion radiotherapy. Lancet Oncol. 2004;5:636–638. DOI: 10.1016/S1470-2045 (04) 01600-6.
6. Elsayad K., Lehrich P., Yppaerilae-Wolters H. et al. Primary cardiac angiosarcoma treated with positron emission tomography/magnetic resonance imaging-guided adaptive radiotherapy. Can J Cardiol. 2016;32:829: e7–829.e10. DOI: 10.1016/j.cjca.2015.07.010.
7. Elsayad K., Scobioala S., Kriz J. et al. Advances in image-guided radiation therapy for primary cardiac angiosarcoma: The role of PET-CT and MRI. Oncol Res Treat. 2016;39:290–294. DOI: 10.1159/000445864.
8. Климанов В.А. Радиобиологическое и дозиметрическое планирование лучевой и радионуклидной терапии. Часть 2. Лучевая терапия пучками протонов, ионов, нейтронов и пучками с модулированной интенсивностью, стереотаксис, брахитерапия, радионуклидная терапия, оптимизация, гарантия качества. Учебное пособие. М.: НИЯУ МИФИ; 2011. [Klimanov V.A. Radiobiological and dosimetric planning of radiation and radionuclide therapy. Part 2. Radiation therapy with proton, ion, neutron and modulated-intensity beams, stereotaxis, brachytherapy, radionuclide therapy, optimization, quality assurance. Tutorial. M.: NRNU MEPhI; 2011 (in Russ.)].
This work is licensed under a Creative Commons «Attribution» 4.0 License.
Распечатать